Reduced cardiotoxicity of doxorubicin given in the form of N-(2-hydroxypropyl)methacrylamide conjugates: and experimental study in the rat
about
HPMA copolymer-1,5-diazaanthraquinone conjugates as novel anticancer therapeutics.In vivo fluorescence imaging of the transport of charged chlorin e6 conjugates in a rat orthotopic prostate tumour.Protease-activated drug development.Cathepsin B-cleavable doxorubicin prodrugs for targeted cancer therapy (Review)Mind the gap: a survey of how cancer drug carriers are susceptible to the gap between research and practice.Polymeric drug-carriers containing doxorubicin and melanocyte-stimulating hormone: in vitro and in vivo evaluation against murine melanoma.Gamma scintigraphy of a 123I-labelled N-(2-hydroxypropyl)methacrylamide copolymer-doxorubicin conjugate containing galactosamine following intravenous administration to nude mice bearing hepatic human colon carcinoma.The activity of doxorubicin niosomes against an ovarian cancer cell line and three in vivo mouse tumour models.Tumour tropism and anti-cancer efficacy of polymer-based doxorubicin prodrugs in the treatment of subcutaneous murine B16F10 melanoma.Image-guided and passively tumour-targeted polymeric nanomedicines for radiochemotherapy.HPMA-based polymer therapeutics improve the efficacy of surgery, of radiotherapy and of chemotherapy combinations.Preclinical evaluation of the cardiotoxicity of PK2: a novel HPMA copolymer-doxorubicin-galactosamine conjugate antitumour agent.Hemodynamic effects of HPMA copolymer based doxorubicin conjugate: A randomized controlled and comparative spectral study in conscious rats.Dual passively active tumor-targeting micelles for pH-triggered intracellular anticancer drug release
P2860
Q30979368-BF24A278-94FE-4B46-8B1A-FB8E9DC1A919Q33178931-90126C3A-B82C-47F6-ADE3-9977ECFE5D8BQ35811508-E777D37B-B5DA-4164-8531-A54E673603EAQ36643541-290CEBEE-13DA-4F13-BD73-32E5F9EAFA52Q37467770-C32C2574-9A43-43A4-A0B5-FD1E7D54AD09Q38569655-C4FB94D5-D356-4C56-8AB1-9166539C97D9Q40957297-562646CC-417D-4D33-AF80-1575DC35B249Q41247187-F28DC66F-1523-4244-A56C-A6F3DABF48CCQ42286030-72FAE710-7A34-46EC-92FD-D02934336639Q42551562-29AE9902-0797-4882-9DD6-4E041BAA4D5BQ42782242-77E49C2F-7625-4D44-846E-D30C28862D2FQ43845018-AFE05468-83AF-48C8-9C72-284EEEBE4474Q50948084-E7CB0621-CC3E-4D2A-855D-DCCBC0F864FDQ57371949-DE4AAA0E-5BD5-4DC6-860B-88801C1597B7
P2860
Reduced cardiotoxicity of doxorubicin given in the form of N-(2-hydroxypropyl)methacrylamide conjugates: and experimental study in the rat
description
1991 nî lūn-bûn
@nan
1991 թուականին հրատարակուած գիտական յօդուած
@hyw
1991 թվականին հրատարակված գիտական հոդված
@hy
1991年の論文
@ja
1991年論文
@yue
1991年論文
@zh-hant
1991年論文
@zh-hk
1991年論文
@zh-mo
1991年論文
@zh-tw
1991年论文
@wuu
name
Reduced cardiotoxicity of doxo ...... experimental study in the rat
@ast
Reduced cardiotoxicity of doxo ...... experimental study in the rat
@en
Reduced cardiotoxicity of doxo ...... experimental study in the rat
@nl
type
label
Reduced cardiotoxicity of doxo ...... experimental study in the rat
@ast
Reduced cardiotoxicity of doxo ...... experimental study in the rat
@en
Reduced cardiotoxicity of doxo ...... experimental study in the rat
@nl
prefLabel
Reduced cardiotoxicity of doxo ...... experimental study in the rat
@ast
Reduced cardiotoxicity of doxo ...... experimental study in the rat
@en
Reduced cardiotoxicity of doxo ...... experimental study in the rat
@nl
P2093
P356
P1476
Reduced cardiotoxicity of doxo ...... experimental study in the rat
@en
P2093
F Spreafico
J Strohalm
J W Hopewell
R H Simmonds
P2888
P304
P356
10.1007/BF00687318
P407
P577
1991-01-01T00:00:00Z
P6179
1039654254